Previous 10 | Next 10 |
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery PR Newswire Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHAN...
2023-09-12 17:59:16 ET Summary Halozyme Therapeutics, based in San Diego, has developed ENHANZE technology based around its proprietary enzyme, rHuPH20. The enzyme makes it possible for many intravenously administered drugs to be administered subcutaneously instead. Not only i...
2023-08-29 07:14:31 ET More on Halozyme, Roche, etc. Halozyme Therapeutics, Inc. ( HALO ) Q2 2023 Earnings Call Transcript Roche: FX Drug But Positive Outlook Roche Holding AG ( OTCQX:RHHBY ) Q2 2023 Earnings Call Transcript Halozyme: Inflection Point...
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain PR Newswire First subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain Tecentriq ® subcutaneous formulation with E...
2023-08-08 21:44:07 ET Halozyme Therapeutics, Inc. (HALO) Q2 2023 Earnings Conference Call August 8, 2023, 04:30 AM ET Company Participants Tram Bui - VP, IR and Corporate Communications Helen Torley - President and CEO Nicole LaBrosse - CFO Conference Call...
2023-08-08 16:04:28 ET Halozyme Therapeutics press release ( NASDAQ: HALO ): Q2 Non-GAAP EPS of $0.74 beats by $0.10 . Revenue of $221.04M (+45.1% Y/Y) beats by $21.09M . Royalty Revenue Increased 31% YOY to Record $111.7 million 2023 Outlook: Total rev...
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS PR Newswire Revenue Increased 45% YOY to $221.0 million ; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.74 1 Royalty Revenue Increased 31% YOY to Record $111.7 millio...
2023-08-07 17:35:58 ET Halozyme Therapeutics ( NASDAQ: HALO ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is $0.64 (+20.8% Y/Y) and the consensus Revenue Estimate is $199.95M (+31.2% Y/Y). Over the...
Halozyme To Report Second Quarter 2023 Financial and Operating Results PR Newswire SAN DIEGO , July 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating re...
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire SAN DIEGO , July 17, 2023 /PRNewswire/ -- Halo...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...